|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||55.32 - 56.51|
|52 Week Range||53.31 - 64.65|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
On January 29, 2018, Sanofi (SNY) announced its acquisition of Ablynx (ABLX), a Belgium-based biopharmaceutical company, for 45 euros per Ablynx share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash. As per the agreement, Sanofi will acquire all outstanding Ablynx ordinary shares, including American depositary shares, warrants, and convertible bonds. The deal was unanimously approved by the boards of directors of both Sanofi and Ablynx.
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.1 billion pounds from the sale of its human immunodeficiency virus (or HIV) products, which is year-over-year (or YoY) growth of 16% on a reported basis and 13% on a constant exchange rate (or CER). The company witnessed sales worth 681 million pounds for its HIV franchise in the US market in 3Q17, which is YoY growth of 21% on a reported basis and 18% on CER basis.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds.